Lazard Asset Management LLC Has $1.99 Million Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Lazard Asset Management LLC boosted its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 42.2% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 10,757 shares of the medical research company's stock after acquiring an additional 3,194 shares during the quarter. Lazard Asset Management LLC's holdings in Charles River Laboratories International were worth $1,985,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the business. Veracity Capital LLC acquired a new position in Charles River Laboratories International in the 4th quarter valued at approximately $589,000. Allspring Global Investments Holdings LLC increased its stake in shares of Charles River Laboratories International by 2.7% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,808,002 shares of the medical research company's stock worth $330,231,000 after acquiring an additional 47,221 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Charles River Laboratories International by 46.4% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,301 shares of the medical research company's stock worth $987,000 after acquiring an additional 1,679 shares in the last quarter. Boston Trust Walden Corp boosted its position in Charles River Laboratories International by 4.3% during the fourth quarter. Boston Trust Walden Corp now owns 204,483 shares of the medical research company's stock valued at $37,748,000 after purchasing an additional 8,338 shares during the last quarter. Finally, E. Ohman J or Asset Management AB grew its stake in Charles River Laboratories International by 225.0% in the fourth quarter. E. Ohman J or Asset Management AB now owns 2,600 shares of the medical research company's stock valued at $480,000 after purchasing an additional 1,800 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on CRL shares. William Blair lowered Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a report on Wednesday, January 22nd. Barclays lifted their target price on shares of Charles River Laboratories International from $145.00 to $155.00 and gave the company an "equal weight" rating in a research note on Thursday, May 8th. Robert W. Baird increased their price target on shares of Charles River Laboratories International from $118.00 to $140.00 and gave the stock a "neutral" rating in a research note on Thursday, May 8th. The Goldman Sachs Group downgraded shares of Charles River Laboratories International from a "buy" rating to a "neutral" rating and cut their price target for the company from $190.00 to $170.00 in a report on Friday, March 21st. Finally, Mizuho decreased their price objective on shares of Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating for the company in a report on Wednesday, April 9th. One analyst has rated the stock with a sell rating, fourteen have given a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $172.31.

Charles River Laboratories International Stock Performance

CRL traded up $2.11 during midday trading on Tuesday, reaching $143.49. The company's stock had a trading volume of 956,394 shares, compared to its average volume of 983,911. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. The company has a fifty day simple moving average of $134.37 and a 200 day simple moving average of $164.34. The stock has a market cap of $7.05 billion, a P/E ratio of 956.60, a PEG ratio of 4.54 and a beta of 1.50. Charles River Laboratories International, Inc. has a twelve month low of $91.86 and a twelve month high of $254.15.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The medical research company reported $2.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.06 by $0.28. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The business had revenue of $984.17 million for the quarter, compared to the consensus estimate of $942.34 million. During the same quarter last year, the company posted $2.27 earnings per share. Charles River Laboratories International's quarterly revenue was down 2.7% on a year-over-year basis. Research analysts expect that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Insider Transactions at Charles River Laboratories International

In related news, EVP Joseph W. Laplume sold 4,400 shares of the business's stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $162.50, for a total transaction of $715,000.00. Following the transaction, the executive vice president now directly owns 20,013 shares in the company, valued at $3,252,112.50. The trade was a 18.02% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Birgit Girshick acquired 1,514 shares of Charles River Laboratories International stock in a transaction on Thursday, February 20th. The stock was purchased at an average price of $164.63 per share, with a total value of $249,249.82. Following the transaction, the chief operating officer now directly owns 55,058 shares in the company, valued at approximately $9,064,198.54. This trade represents a 2.83% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have sold 5,040 shares of company stock worth $807,407. 1.30% of the stock is currently owned by company insiders.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).